PYXS - RN and gil, I think you guys have it right. It appears to be Pyxis licensing from Pfizer and this was a payment to Pfizer, which gives it a different perspective. Could still be a good thing, but common sense suggests Pfizer isn't selling off their best drug candidates. Who knows, maybe Pfizer loves the Pyxis team and thinks they could do it best. But might also be some house-cleaning on Pfizer's part -- sell off (for cash and shares) the drug candidates that you're not that high on so you can focus on the good stuff.
Pyxis had couple hundred million in cash in last 10-Q, but also burning thru it at a furious pace of roughly $100m per year, so might be down to $175m now.
